{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:02:50Z","timestamp":1781326970933,"version":"3.54.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Alectinib is effective in extending the survival of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and generally has manageable side effects. However, intestinal ulcers and colitis are rare but serious adverse reactions linked to Alectinib, meriting further investigation into their causes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We report the case of a 62-year-old woman with NSCLC and brain metastases, who tested positive for ALK. She had been treated with Alectinib for nearly 4\u00a0years. The patient experienced diarrhea for 4\u00a0days, and a subsequent colonoscopy revealed pancolitis along with multiple ulcers in the terminal ileum and ileocecal valve. Given the severity of these symptoms, classified as a grade 3 adverse event by the Common Terminology Criteria for Adverse Events (CTCAE), Alectinib was discontinued. Treatment with oral enteric-coated Mesalazine tablets led to a resolution of the diarrhea and a significant improvement in the pancolitis and ulcers upon follow-up. The patient\u2019s anticancer therapy was subsequently switched to Ceritinib capsules. At follow-up, she demonstrated a stable tumor condition with no recurrence of intestinal ulcers or colitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>To our knowledge, this is the first reported case of intestinal ulceration and colitis induced by Alectinib. Although such adverse events are exceedingly rare, they require vigilant monitoring in clinical practice. Decisions on continuing with Alectinib should consider the severity of side effects, classified by CTCAE grade. For managing these specific adverse events, oral Mesalazine enteric-coated tablets appear to be an effective treatment option.<\/jats:p><\/jats:sec>","DOI":"10.3389\/pore.2025.1612040","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T04:11:27Z","timestamp":1741234287000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case report: Alectinib-associated intestinal ulceration and colitis in a patient with non-small cell lung cancer and effective treatment with Mesalazine"],"prefix":"10.3389","volume":"31","author":[{"given":"Zijian","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1097\/JTO.0b013e3181c4dedb","article-title":"ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer","volume":"4","author":"Solomon","year":"2009","journal-title":"J Thorac Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/cncr.34664","article-title":"Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: a systematic review and network meta-analysis","volume":"129","author":"Peng","year":"2023","journal-title":"Cancer."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1158\/2159-8290.CD-24-0231","article-title":"NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations","volume":"14","author":"Lin","year":"2024","journal-title":"Cancer Discov"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100612","DOI":"10.1016\/j.esmoop.2022.100612","article-title":"Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib","volume":"7","author":"Dziadziuszko","year":"2022","journal-title":"ESMO Open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/10781552221102370","article-title":"Avascular necrosis during alectinib treatment: case report","volume":"29","author":"G\u00fcrsoy","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100606","DOI":"10.1016\/j.jtocrr.2023.100606","article-title":"Spontaneous bilateral chylothorax development during alectinib therapy for ALK-rearranged NSCLC-A case report","volume":"4","author":"Bajaj","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13256-018-1849-y","article-title":"Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature","volume":"12","author":"Ramachandran","year":"2018","journal-title":"J Med Case Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/OTT.S398375","article-title":"Alectinib-induced severe hemolytic anemia in a patient with ALK-positive non-small cell lung cancer: a case report","volume":"16","author":"Misawa","year":"2023","journal-title":"Onco Targets Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"944685","DOI":"10.3389\/fphar.2022.944685","article-title":"Case report: indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"104601","DOI":"10.1016\/j.amsu.2022.104601","article-title":"Alectinib-associated pneumoperitoneum in stage IV non-small cell lung cancer - a case report","volume":"82","author":"Maina","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001301","article-title":"Alectinib-associated perforated duodenal ulcer","author":"Patel","year":"2020","journal-title":"Am J Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"107319","DOI":"10.1016\/j.lungcan.2023.107319","article-title":"Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: systematic review and network meta-analysis","volume":"184","author":"Luo","year":"2023","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature01950","article-title":"Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion","volume":"425","author":"Englund","year":"2003","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1097\/PAS.0000000000001512","article-title":"Colorectal adenocarcinomas harboring ALK fusion genes: a clinicopathologic and molecular genetic study of 12 cases and review of the literature","volume":"44","author":"Lasota","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1002\/ijc.30699","article-title":"Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats","volume":"140","author":"Van Sebille","year":"2017","journal-title":"Int J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20180992","article-title":"Apoptosis and apoptotic body: disease message and therapeutic target potentials","volume":"39","author":"Xu","year":"2019","journal-title":"Biosci Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1094598","DOI":"10.1080\/2162402X.2015.1094598","article-title":"Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: implication for optional anti-PD-1\/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients","volume":"5","author":"Hong","year":"2016","journal-title":"Oncoimmunology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1093\/jcag\/gwad012","article-title":"The 2023 impact of inflammatory bowel disease in Canada: mental health and inflammatory bowel disease","volume":"6","author":"Graff","year":"2023","journal-title":"J Can Assoc Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"101560","DOI":"10.1016\/j.esmoop.2023.101560","article-title":"Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors","volume":"8","author":"Zhou","year":"2023","journal-title":"ESMO Open"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2025.1612040\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T04:11:35Z","timestamp":1741234295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2025.1612040\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":24,"alternative-id":["10.3389\/pore.2025.1612040"],"URL":"https:\/\/doi.org\/10.3389\/pore.2025.1612040","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"article-number":"1612040"}}